LivaNova PLC Financials
LIVN Stock | USD 51.70 1.65 3.30% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.44 | 0.4592 |
|
| |||||
Current Ratio | 5.04 | 2.9499 |
|
|
The financial analysis of LivaNova PLC is a critical element in measuring its lifeblood. Investors should not minimize LivaNova PLC's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
LivaNova | Select Account or Indicator |
Understanding current and past LivaNova PLC Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of LivaNova PLC's financial statements are interrelated, with each one affecting the others. For example, an increase in LivaNova PLC's assets may result in an increase in income on the income statement.
LivaNova PLC Earnings Geography
LivaNova PLC Stock Summary
LivaNova PLC competes with Orthopediatrics Corp, Pulmonx Corp, Si Bone, Neuropace, and Globus Medical. LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom. Livanova Plc operates under Medical Equipment classification in the United States and is traded on NASDAQ Exchange. It employs 3000 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | GB00BYMT0J19 |
CUSIP | G5509L101 |
Location | United Kingdom |
Business Address | 20 Eastbourne Terrace, |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.livanova.com |
Phone | 44 20 3325 0660 |
Currency | USD - US Dollar |
LivaNova PLC Key Financial Ratios
Return On Equity | 0.0187 | ||||
Profit Margin | 0.02 % | ||||
Operating Margin | 0.14 % | ||||
Price To Sales | 2.26 X | ||||
Revenue | 1.15 B |
LivaNova PLC Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.4B | 2.4B | 2.2B | 2.3B | 2.4B | 2.6B | |
Other Current Liab | 342.6M | 187.3M | 364.5M | 163.5M | 193.6M | 203.3M | |
Net Debt | 322.6M | 445M | 67.4M | 356.8M | 373.9M | 392.6M | |
Retained Earnings | (406.8M) | (752.4M) | (897.8M) | (984.0M) | (966.5M) | (918.2M) | |
Cash | 61.1M | 252.8M | 208M | 214.2M | 266.5M | 279.8M | |
Inventory | 164.2M | 126.7M | 105.8M | 129.4M | 147.9M | 155.3M | |
Other Current Assets | 28.5M | 155.6M | 180.0M | 358.1M | 406.0M | 426.3M | |
Total Liab | 1.0B | 1.3B | 906.4M | 1.1B | 1.2B | 1.2B | |
Total Current Assets | 549.4M | 719.4M | 679.2M | 886.1M | 988.2M | 1.0B | |
Short Term Debt | 77.4M | 24.6M | 240.9M | 32.8M | 26.5M | 25.1M | |
Net Receivables | 257.8M | 184.4M | 185.4M | 183.1M | 215.1M | 225.8M | |
Common Stock | 76.3M | 76.3M | 82.3M | 82.4M | 82.5M | 86.7M | |
Long Term Debt | 260.3M | 642.3M | 9.8M | 518.1M | 568.5M | 597.0M | |
Other Liab | 209.1M | 299M | 163.7M | 242.1M | 278.5M | 292.4M | |
Treasury Stock | (1.5M) | (1.3M) | (1.0M) | (650K) | (747.5K) | (784.9K) | |
Intangible Assets | 607.5M | 437.6M | 399.7M | 368.6M | 261.2M | 344.0M | |
Net Tangible Assets | (139.6M) | (241.1M) | (4.6M) | 70.3M | 63.3M | 116.1M | |
Good Will | 915.8M | 922.3M | 899.5M | 768.8M | 782.9M | 895.7M | |
Short Long Term Debt | 77.4M | 13.3M | 229.7M | 23.4M | 18.1M | 17.2M |
LivaNova PLC Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 14.3M | 40.7M | 49.7M | 48.3M | 58.9M | 61.8M | |
Total Revenue | 1.1B | 934.2M | 1.0B | 1.0B | 1.2B | 1.2B | |
Gross Profit | 744.8M | 618.2M | 706M | 707.2M | 771.3M | 809.8M | |
Operating Income | 48M | (42.8M) | (900K) | 52.7M | (68.5M) | (65.1M) | |
Ebit | 48M | (307.2M) | (74.3M) | (26.9M) | (21.8M) | (20.7M) | |
Ebitda | 131M | (225.9M) | (6.3M) | 30.9M | 39.0M | 28.9M | |
Cost Of Revenue | 339.4M | 316M | 329.4M | 314.6M | 382.3M | 401.4M | |
Income Before Tax | (185.7M) | (344M) | (124.5M) | (75.1M) | (81.2M) | (77.2M) | |
Net Income | (155.5M) | (343.3M) | (135.7M) | (86.2M) | 17.5M | 18.4M | |
Income Tax Expense | (30.2M) | (700K) | 11.2M | 11.1M | (98.9M) | (93.9M) | |
Research Development | 149.9M | 152.9M | 183.4M | 155.8M | 193.8M | 203.5M | |
Tax Provision | (30.2M) | (700K) | 11.2M | 11.1M | 16.5M | 17.3M | |
Interest Income | 803K | 131K | 435K | 4.7M | 20.1M | 21.1M | |
Net Interest Income | (14.3M) | (40.7M) | (49.7M) | (43.6M) | (36.5M) | (38.4M) |
LivaNova PLC Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 13.9M | 191.7M | (44.8M) | 307.6M | 62.3M | 65.4M | |
Free Cash Flow | (119.1M) | (114.4M) | 77M | 43.4M | 39.9M | 41.9M | |
Other Non Cash Items | 33M | 222.9M | 100.9M | 83.8M | 109.2M | 114.7M | |
Capital Expenditures | 28M | 35M | 25.5M | 26.5M | 35.0M | 36.7M | |
Net Income | (155.2M) | (345M) | (135.8M) | (86.2M) | 17.5M | 18.4M | |
End Period Cash Flow | 61.1M | 252.8M | 208M | 515.6M | 577.9M | 606.8M | |
Investments | (41.3M) | (5.9M) | 19.4M | (38.4M) | (39.1M) | (37.2M) | |
Net Borrowings | 171.8M | 339.3M | (487.9M) | 284.0M | 326.6M | 342.9M | |
Change To Netincome | 167.6M | 261.3M | 124.4M | 108.7M | 125.0M | 97.0M | |
Change Receivables | (48.9M) | 21.2M | 58.8M | (15.7M) | (18.1M) | (17.2M) |
LivaNova Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining LivaNova PLC's current stock value. Our valuation model uses many indicators to compare LivaNova PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across LivaNova PLC competition to find correlations between indicators driving LivaNova PLC's intrinsic value. More Info.LivaNova PLC is rated below average in return on equity category among its peers. It is rated fourth overall in return on asset category among its peers reporting about 2.32 of Return On Asset per Return On Equity. At this time, LivaNova PLC's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the LivaNova PLC's earnings, one of the primary drivers of an investment's value.LivaNova PLC's Earnings Breakdown by Geography
LivaNova PLC Systematic Risk
LivaNova PLC's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. LivaNova PLC volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on LivaNova PLC correlated with the market. If Beta is less than 0 LivaNova PLC generally moves in the opposite direction as compared to the market. If LivaNova PLC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one LivaNova PLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of LivaNova PLC is generally in the same direction as the market. If Beta > 1 LivaNova PLC moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in LivaNova PLC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various LivaNova PLC's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of LivaNova PLC growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
LivaNova PLC November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of LivaNova PLC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of LivaNova PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of LivaNova PLC based on widely used predictive technical indicators. In general, we focus on analyzing LivaNova Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build LivaNova PLC's daily price indicators and compare them against related drivers.
Downside Deviation | 1.77 | |||
Information Ratio | 0.0417 | |||
Maximum Drawdown | 8.68 | |||
Value At Risk | (2.55) | |||
Potential Upside | 3.73 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LivaNova PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in LivaNova Stock, please use our How to Invest in LivaNova PLC guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LivaNova PLC. If investors know LivaNova will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about LivaNova PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 14 | Earnings Share 0.43 | Revenue Per Share 22.907 | Quarterly Revenue Growth 0.112 | Return On Assets 0.0434 |
The market value of LivaNova PLC is measured differently than its book value, which is the value of LivaNova that is recorded on the company's balance sheet. Investors also form their own opinion of LivaNova PLC's value that differs from its market value or its book value, called intrinsic value, which is LivaNova PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because LivaNova PLC's market value can be influenced by many factors that don't directly affect LivaNova PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between LivaNova PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if LivaNova PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, LivaNova PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.